MAPK signaling pathway

Overview

The MAPK signaling pathway is a conserved intracellular signaling network that transduces extracellular and intracellular stimuli into coordinated cellular responses. It is commonly discussed as a family of mitogen-activated protein kinase cascades, including ERK-, JNK-, and p38-related branches, which regulate processes such as cell proliferation, differentiation, stress responses, inflammation, apoptosis, and immune signaling. Because of this broad regulatory role, MAPK signaling is frequently implicated in cancer biology, inflammatory disease, tissue injury, and host defense.

In biomedical research, the pathway is often studied as a mechanistic node linking upstream receptors and stress signals to downstream transcriptional and post-translational responses. In the recent literature provided here, MAPK signaling appears as a target of pharmacologic modulation in psoriasis-like skin inflammation, melanoma cell migration and invasion, immune regulation in triple-negative breast cancer, anti-inflammatory compound screening, cardiovascular injury, and multi-pathway disease models involving NF-κB, PI3K/Akt, JAK-STAT, toll like receptor 4 (TLR4), and oxidative stress.

Recent Publications Summary

Recent publications on the MAPK signaling pathway largely examined its role as a therapeutic target in cancer and inflammatory disease, often using network pharmacology, molecular docking, in vitro assays, and animal models. In KRAS-mutant non-small cell lung cancer, a computational repurposing workflow identified nilotinib and risperidone as high-affinity candidates across MAPK pathway targets, and follow-up functional testing showed that nilotinib reduced cell viability, colony formation, angiogenesis, migration, and induced apoptosis in NSCLC models 42595781Aug. In another NSCLC-focused study, the traditional Chinese medicine Fei Jin Sheng formula was reported to exert antitumor effects in vivo by decreasing ERK1/2, p-ERK1/2, MEK1/2, and p-MEK1/2 expression, consistent with inhibition of MAPK signaling 42461333Jul. In cholangiocarcinoma, ZDHHC5-mediated palmitoylation of BRAF at Cys194/195 promoted membrane localization and stabilization of BRAF, activated ERK signaling, and increased sensitivity to MAPK pathway inhibitors when ZDHHC5 was highly expressed 42134490May.

Several studies also described MAPK modulation as part of anti-inflammatory or tissue-protective mechanisms. Vasicine derivatives were evaluated as potential psoriasis treatments, and compound 4r attenuated psoriasis-like skin inflammation by inhibiting MAPK signaling activation in vivo and in HaCaT cells 41269571Nov. Syncarpic acid derivatives 5c and 9a showed anti-inflammatory activity, with western blot results indicating that their effects were mediated at least in part through MAPK pathway modulation 42136121May. Similarly, bioactive compounds from Angelica dahurica were reported to attenuate LPS-induced inflammation via dual inhibition of MAPK and NF-κB signaling pathways 41687945Feb. Tranexamic acid was also investigated for protecting human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway 42059427Apr. In a cardiotoxicity model, kaempferol from Modified Huanglian Jiedu Decoction antagonized jellyfish venom-induced cardiomyocyte injury by inhibiting MAPK signaling 41903811Mar, and Aconitum septentrionale extract was reported to alleviate cigarette smoke and lipopolysaccharide-induced chronic obstructive pulmonary disease in mice by modulating the MAPK pathway 41864552Mar.

Other reports linked MAPK signaling to tumor biology, immune regulation, and treatment resistance. In lung adenocarcinoma, GAB3 was identified as a tumor suppressor that inhibited MAPK signaling through interaction with LYN kinase, while also enhancing CD8+ T cell immunity and sensitizing tumors to anti-PD-1 therapy 42031161Apr. In aggressive thyroid Cancers harboring BRAFV600E, ETV5 was associated with p38/MAPK14 activation, and combined p38 inhibition with dabrafenib showed strong in vitro synergy, including in resistant cells 41544239Jan. A SIN1-targeting inhibitor was reported to block wild-type RAS activation and downstream MAPK signaling while suppressing cancer cell proliferation across multiple cell lines 41423418Dec. In radioiodine-refractory differentiated thyroid cancer, genotype-guided MAPK inhibition combined with individualized dosimetry was evaluated as a redifferentiation strategy 41686811Feb. Additional studies associated MAPK signaling with acute ischemic stroke through an m7G RNA methylation-related signature 42335089Jun, with MAPK1 and other pathway components in hepatocellular carcinoma drug discovery 41855633Mar, and with cancer epigenetic therapy resistance in MECP2-dependent models where activated RAS and other MAPK activators reduced therapeutic sensitivity 41379640Dec.

Overall, these publications portray MAPK signaling as a recurring mechanistic node in oncogenesis, inflammation, and stress-related injury, with studies emphasizing pathway inhibition, pathway reprogramming, and combination strategies. Reported experimental approaches ranged from virtual screening and molecular dynamics to xenografts, chemically induced disease models, immunohistochemistry, and cell-based functional assays, reflecting broad interest in targeting MAPK signaling for both direct antitumor effects and modulation of inflammatory or degenerative processes 42595781Aug42461333Jul42134490May41269571Nov41687945Feb42031161Apr41544239Jan41423418Dec.

What Changes, What Holds

1. MAPK inhibition is being extended into additional oncologic settings and drug-repurposing workflows
REINFORCES Nilotinib, risperidone, and Fei Jin Sheng formula all fit the established view of MAPK signaling as a therapeutic node in cancer rather than revising it, and the cholangiocarcinoma palmitoylation finding adds a mechanistic layer by showing upstream control of BRAF stability and MAPK inhibitor sensitivity 42595781Aug42461333Jul42134490May. What changes is not the pathway’s core role, but the range of actionable inputs and the plausibility of combination or repurposing strategies.

2. MAPK modulation remains a common anti-inflammatory and tissue-protective mechanism
REINFORCES Vasicine derivatives, syncarpic acid derivatives, Angelica dahurica compounds, tranexamic acid, kaempferol, and Aconitum septentrionale all strengthen the baseline picture of MAPK signaling as a frequent mediator of inflammatory and injury responses, especially in skin, lung, fibroblast senescence, and cardiotoxicity models 41269571Nov41687945Feb. Nothing here overturns the established account; instead, it reinforces MAPK as a recurring target when authors seek to dampen inflammation or protect stressed tissue.

3. MAPK signaling is also implicated in immune escape, resistance, and genotype-specific vulnerabilities
REINFORCES GAB3’s suppression of MAPK signaling alongside improved CD8+ T cell immunity, p38-linked synergy in BRAFV600E thyroid cancer, SIN1-targeted blockade of wild-type RAS/MAPK output, and genotype-guided redifferentiation strategies all extend the baseline’s cancer biology framing without displacing it 42031161Apr41544239Jan41423418Dec41686811Feb. The new nuance is that pathway status may help define who benefits from combination therapy or immune sensitization, but the pathway’s central oncogenic relevance remains unchanged.

4. The recent literature mainly broadens MAPK’s therapeutic and mechanistic reach rather than revising its core biology
REINFORCES Acute ischemic stroke, hepatocellular carcinoma drug discovery, and epigenetic therapy resistance add new disease contexts and reinforce the idea that MAPK sits at a convergent stress-and-treatment response node, while the mix of docking, xenograft, and cell-based assays shows how the field is operationalizing that idea 42335089Jun41855633Mar41379640Dec. No paragraph here requires abandoning the baseline account; the main update is broader application and stronger emphasis on combination-oriented intervention.

Overview update candidates: BRAF palmitoylation as a regulator of MAPK inhibitor sensitivity in cholangiocarcinoma; MAPK-linked immune sensitization and resistance stratification in cancer therapy.